Paper Details

  1. Home
  2. Paper Details

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.

Author: ArribasJose R, BlochMark, ChuckSusan, CohenCalvin, De-OertelShampa, EbrahimiRamin, FralichTodd, HenryKeith, PorterDanielle, TownerWilliam, Van LunzenJan, WalkerIvan, WhiteKirsten, WilkinsEdmund, WohlDavid

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A phase 3b randomized controlled trial comparing rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in treatment-naive HIV-1-infected adults found that RPV/FTC/TDF was noninferior to EFV/FTC/TDF at week 48 for HIV-1 RNA less than 50 copies/ml. RPV/FTC/TDF demonstrated a statistically significant difference in efficacy compared with EFV/FTC/TDF for participants with baseline HIV-1 RNA 100000 copies/ml or less. RPV/FTC/TDF also demonstrated improved tolerability compared with EFV/FTC/TDF.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To compare the safety and efficacy of the two single-tablet regimens (STRs), rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF), in HIV-1-infected, treatment-naive adults. DESIGN: This is a phase 3b, randomized, o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0000000000000169

データ提供：米国国立医学図書館（NLM）

Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate: A Single-Tablet Regimen for HIV Treatment

HIV, a chronic viral infection, requires lifelong treatment to manage the virus and prevent complications. This study compares the efficacy and safety of two single-tablet regimens (STRs) for treating HIV-infected, treatment-naive adults: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF). STRs offer a convenient and user-friendly approach to HIV treatment, making it easier for patients to adhere to their medication regimens.

The researchers found that RPV/FTC/TDF was noninferior to EFV/FTC/TDF in terms of viral suppression at week 48, with a significantly higher proportion of participants achieving undetectable viral loads in those with lower baseline viral loads. RPV/FTC/TDF also demonstrated improved tolerability compared to EFV/FTC/TDF, with fewer adverse events leading to treatment discontinuation. The findings suggest that RPV/FTC/TDF may be a valuable alternative to EFV/FTC/TDF for treatment-naive adults with HIV, particularly those with lower baseline viral loads.

A New Dawn for HIV Treatment

This study highlights the advancements in HIV treatment with the development of effective and well-tolerated STRs. The findings suggest that RPV/FTC/TDF could be a valuable option for treating HIV-infected adults, particularly those with lower baseline viral loads.

Navigating the Path to HIV Control

This research provides valuable insights into the ongoing search for effective and convenient treatments for HIV. The study emphasizes the importance of STRs in improving adherence to treatment regimens and potentially improving outcomes for patients with HIV.

Dr. Camel's Conclusion

The journey of living with HIV can be long and challenging. This research is like a clear oasis in the desert, highlighting the advancements in HIV treatment with the development of effective and well-tolerated STRs, offering hope and better management for patients living with HIV.

Date :
  1. Date Completed 2015-05-18
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

24508782

DOI: Digital Object Identifier

10.1097/QAD.0000000000000169

Related Literature

Article Analysis
・Side Effects of rilpivirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.